These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21321066)

  • 1. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
    McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
    Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
    Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
    Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
    Warren NJH; Eastman A
    J Biol Chem; 2019 Feb; 294(6):1763-1778. PubMed ID: 30573684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
    Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J
    Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
    Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
    Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
    King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
    Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
    Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
    Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
    Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
    Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
    Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
    Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
    Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.